IL1B and diabetes mellitus: Interestingly, the beneficial effects of IL-1β antagonism on atherosclerosis occurred despite no effect on low-density lipoprotein cholesterol levels and incident DM, indicating that MACE reduction was not dependent on the improvement of dyslipidemia or prevention of DM onset during the study [8,47,48].